Export this record

Export record to excel

File type to download

Beta version

Select record 2

ArticlesPeer ReviewedFull Text

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

Author / Creator:Kuemmel, Sherko, Prof ; Graeser, Monika, PD MD ; Schmid, Peter, Prof ; Reinisch, Mattea, MD ; Feuerhake, Friedrich, Prof ; Volk, Valery, PhD ; Armeanu-Ebinger, Sorin, Prof ; Schütz, Leon, MSc ; Kelemen, Olga, PhD ; Schroeder, Christopher, MD ; Ossowski, Stephan, Prof ; Jóźwiak, Katarzyna, PhD ; Kostara, Athina, MD ; Scheffen, Iris, MD ; Lüdtke-Heckenkamp, Kerstin, MD ; Hilpert, Felix, Prof ; Kentsch, Angela, MD ; Ziske, Carsten, MD ; Depenbusch, Reinhard, MD ; Braun, Michael, Prof ; Blohmer, Jens Uwe, Prof ; zu Eulenburg, Christine, PD PhD ; Christgen, Matthias, Prof ; Bartels, Stephan, PhD ; Kreipe, Hans Heinrich, Prof ; Wuerstlein, Rachel, PD MD ; Biehl, Claudia, MD ; Pelz, Enrico, MD ; Hartkopf, Andreas, Prof ; Harbeck, Nadia, Prof ; Gluz, Oleg, PD MD

Publisher:England: Elsevier Ltd

Journal title:The lancet oncology, 2025-05, Vol.26 (5), p.629-640

View online as a Library member

Export record to excel

Export this record

Export record to excel

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes...

Export this record

Export record to excel

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

Refine your search